Kei Muro
Impact in
- Oncology top 0.05%
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Surgical Treatments
- Gastroenterology top 0.1%
- Gastrointestinal Tumor Research and Treatment
Papers in
- Oncology 239
- Colorectal Cancer Treatments and Studies 157
- Cancer Immunotherapy and Biomarkers 37
- Cancer Treatment and Pharmacology 27
-
- Gastric Cancer Management and Outcomes 175
- Lung Cancer Treatments and Mutations 32
- Co-authors
- Atsushi Ohtsu (57 shared papers)Yasuhiro Shimada (32 shared papers)Takashi Ura (84 shared papers)Yoshito Komatsu (40 shared papers)Narikazu Boku (47 shared papers)Kohei Shitara (73 shared papers)Yasuhide Yamada (33 shared papers)Eric Van Cutsem (24 shared papers)
- Journals
- Annals of Oncology (84 papers)Gastric Cancer (29 papers)International Journal of Clinical Oncology (28 papers)Japanese Journal of Clinical Oncology (24 papers)Esophagus (20 papers)
- Partner nations
- JapanUnited StatesSouth Korea
In The Last Decade
Kei Muro
490 papers receiving 32.9k citations
Kei Muro's Hit Papers
Peers
Comparison fields: 5 of 152
- Oncology 16.1k
- Gastroenterology 2.1k
- Pulmonary and Respiratory Medicine 10.0k
- Hepatology 1.7k
- Surgery 7.1k
Countries citing papers authored by Kei Muro
This map shows the geographic impact of Kei Muro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kei Muro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kei Muro more than expected).
Fields of papers citing papers by Kei Muro
This network shows the impact of papers produced by Kei Muro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kei Muro. The network helps show where Kei Muro may publish in the future.
Co-authors
The 25 scholars most cited alongside Kei Muro, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 506 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | ESMO consensus guidelines for the management of patients with metastatic colorectal cancer Hit paper breakdown → | 2016 | 2659 |
| 2 | Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial Hit paper breakdown → | 2014 | 1964 |
| 3 | Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2017 | 1862 |
| 4 | Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer Hit paper breakdown → | 2017 | 1780 |
| 5 | Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Hit paper breakdown → | 2018 | 1481 |
| 6 | Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer Hit paper breakdown → | 2019 | 1405 |
| 7 | Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial Hit paper breakdown → | 2018 | 1056 |
| 8 | Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial Hit paper breakdown → | 2016 | 932 |
| 9 | Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer Hit paper breakdown → | 2020 | 832 |
| 10 | Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort Hit paper breakdown → | 2016 | 715 |
| 11 | Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. | 2000 | 656 |
| 12 | Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer Hit paper breakdown → | 2011 | 613 |
| 13 | 2004 | 545 | |
| 14 | Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer Hit paper breakdown → | 2015 | 521 |
| 15 | Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E-Mutant Colorectal Cancer Hit paper breakdown → | 2018 | 492 |
| 16 | Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS Hit paper breakdown → | 2017 | 460 |
| 17 | Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study Hit paper breakdown → | 2013 | 408 |
| 18 | 1999 | 375 | |
| 19 | Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012 Hit paper breakdown → | 2018 | 368 |
| 20 | Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer Hit paper breakdown → | 2017 | 365 |
About Kei Muro
Kei Muro is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Surgery, Gastroenterology and Hepatology, having authored 506 papers that have together received 33.4k indexed citations. Recurring topics across this work include Gastric Cancer Management and Outcomes (175 papers), Colorectal Cancer Treatments and Studies (157 papers), Esophageal Cancer Research and Treatment (74 papers), Cancer Immunotherapy and Biomarkers (37 papers), Lung Cancer Treatments and Mutations (32 papers), Gastrointestinal Tumor Research and Treatment (29 papers), Cancer Treatment and Pharmacology (27 papers) and Hepatocellular Carcinoma Treatment and Prognosis (20 papers). The work is most often cited by research in Oncology (16.1k citations), Gastroenterology (2.1k citations), Pulmonary and Respiratory Medicine (10.0k citations), Hepatology (1.7k citations) and Surgery (7.1k citations). Kei Muro has collaborated with scholars based in Japan, United States and South Korea. Frequent co-authors include Atsushi Ohtsu, Yasuhiro Shimada, Takashi Ura, Yoshito Komatsu, Narikazu Boku, Kohei Shitara, Yasuhide Yamada, Eric Van Cutsem, Shuichi Hironaka and Kuniaki Shirao. Their work appears in journals such as Annals of Oncology, Gastric Cancer, International Journal of Clinical Oncology, Japanese Journal of Clinical Oncology and Esophagus.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.